Starling Oncology closed at $6.70 on Nov 5, down 3.46%, 5.0% below its highest close since Sep 11. Volume of 2.1M shares was 1.59× its 20-day average (above normal).
Split-adjusted performance: +4.2% over one month.
Short interest was 6.5M shares at the Oct 15 settlement, down 3.8% from the prior report (9.0% of float, 5.6 days to cover).
No reported quarters with price history yet.
Percentile among 7 companies (100 = best)
Industry medians: 6-month return −6.2%, revenue growth −2.5%, net margin −4.5%, P/E 10.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| STLNStarling Oncology | $6.70 | −3.46% | — | — | — | — | $682.8M | |
| SBCSBC Medical Group Holdings Incorporated | $5.02 | −5.64% | +56.4% | +13.4% | 21.7% | 10.5 | $516.3M | Compare |
| TDOCTeladoc Health | $9.41 | −2.99% | +35.2% | −3.4% | −4.5% | — | $1.72B | Compare |
| LFMDLifeMD | $2.29 | −6.53% | −49.0% | −3.5% | −16.6% | — | $110.5M | Compare |
| AIRSAirSculpt Technologies | $1.44 | −15.29% | −58.4% | −2.5% | −2.6% | — | $103.8M | Compare |
| HIMSHims & Hers Health | $24.06 | −9.75% | −6.2% | +38.2% | −11.5% | — | $5.61B | Compare |
| WSTNWestin Acquisition | $10.23 | −0.29% | — | — | — | — | $80.9M | Compare |
No recent articles focused on Starling Oncology. 1 articles mention it in passing.
Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
